POLLEN GRAINS AS TROJAN HORSES FOR ORAL VACCINATION
POLLEN GRAINS AS TROJAN HORSES FOR ORAL VACCINATION
批准号:
8356940
负责人:
Harvinder Singh Gill
金额:
$220.5万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-09-30 至 2017-08-31
关键词:
AddressAdjuvantAntibodiesAntigensBiomedical EngineeringCell LineCerealsChildCholera ToxinCommunicable DiseasesDataDevelopmentDrug Delivery SystemsEngineeringEnvironmentEpithelialEpithelial CellsEquus caballusGoalsGoldHumanHuman bodyImmune responseImmunoglobulin GInfectionIntestinesIntramuscularMethodologyMicrobeModelingMucosal Immune ResponsesMucosal ImmunityMucous MembraneMusNeedlesOralOvalbuminPainlessPollenRouteSerumStomachSurfaceTestingVaccinationVaccine AntigenVaccinesabstractingbasefeedingfightinggastrointestinalhypodermic needleimmunoregulationinterdisciplinary approachmicrobialmucosal vaccinenoveloral vaccineparticlepathogenpublic health relevanceuptakevaccine deliveryvaccinology
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (Provided by the applicant)
Abstract: We propose to transform pollen grains into a powerful and broadly applicable oral vaccination platform. Oral vaccine delivery has been a longstanding goal in the field of vaccination because it is needle-free, can be selfadministered and can produce both systemic and mucosal immune responses. Mucosal immunity is a powerful host-regulated defense at the mucosal surfaces that can neutralize pathogens while they are still outside the human body, before they can cause infection. The gastrointestinal mucosa like other mucosal surfaces suffers from constant onslaughts of microbes and forms a major portal of pathogen entry. Therefore, being able to stimulate mucosal immunity at the gastrointestinal mucosa will offer a tremendous immunological advantage to humans to help fight-off microbial invasions. The major roadblocks that continue to obstruct successful oral vaccination are the degradation of vaccines in the stomach and their poor uptake across the intestinal epithelial cell lining. Pollen
grains are a natural engineering marvel with potential to address these roadblocks. Pollen grains have very tough exterior shells, which can withstand the acidic and enzymatic environment of the stomach and they can pass in to the body as intact particles across the tight epithelial cells of the gastrointestinal mucosa. We propose to exploit these fantastic natural particles and transform them into ¿Trojan horses¿ to safely ferry vaccine antigens across the harsh environment of the stomach and across the tight epithelial barrier, into the body. We have tested the feasibility of our seemingly peculiar idea by feeding mice with pollen grains filled with ovalbumin as a model antigen. Anti-ovalbumin immunoglobulin G (IgG) antibodies were produced in mouse serum after the vaccination. Importantly, the anti-ovalbumin IgG levels induced by pollen grains were found to be more than ten-fold higher than the anti-ovalbumin IgG levels induced by the use of cholera toxin (CT) as a positive control. This result is very significant because CT as a mucosal adjuvant is the current gold standard for oral vaccination and our data suggests that pollen grains are superior to CT. We are very excited by this discovery and we propose to further develop this promising strategy for oral vaccination through a multidisciplinary approach bridging the fundamentals of bioengineering, drug delivery and vaccinology. Our two complementary goals that will move this approach closer to human trials are: (i) characterize pollen grains and develop a mechanistic understanding of their Trojan
ability, and (ii) understand mucosal and systemic immune responses generated by pollen grain-based oral vaccination and explore the potential of immunomodulation by the synergistic use of adjuvants. Overall, this pollen grain-based oral vaccine delivery platform is expected to be highly versatile and thus has potential to be harnessed for development of mucosal vaccines against a host of infectious diseases.
Public Health Relevance: This project seeks to develop a novel methodology for oral vaccination, which is painless, child-friendly, safer and functionally superior to the exiting intramuscular route of vaccination using hypodermic needles. The delivery methodology will have broad applicability and will be able to deliver a broad range of vaccines.
期刊论文(8)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1080/17425247.2021.1946511
发表时间:
2021-10
期刊:
Expert opinion on drug delivery
影响因子:
6.6
作者:
[Gonzalez-Cruz P, Gill HS]
通讯作者:
Gill HS
DOI:
10.1016/j.ijpharm.2018.10.016
发表时间:
2018-12-01
期刊:
International journal of pharmaceutics
影响因子:
5.8
作者:
[Lale SV, Gill HS]
通讯作者:
Gill HS
DOI:
10.1016/j.jconrel.2014.08.010
发表时间:
2014-11-28
期刊:
Journal of controlled release : official journal of the Controlled Release Society
影响因子:
--
作者:
[Atwe SU, Ma Y, Gill HS]
通讯作者:
Gill HS
DOI:
10.1016/j.ijpharm.2018.05.003
发表时间:
2018-07-10
期刊:
International journal of pharmaceutics
影响因子:
5.8
作者:
[Uddin MJ, Gill HS]
通讯作者:
Gill HS
DOI:
10.1016/j.jconrel.2017.10.019
发表时间:
2017-12-28
期刊:
Journal of controlled release : official journal of the Controlled Release Society
影响因子:
--
作者:
[Uddin MJ, Gill HS]
通讯作者:
Gill HS
共 6 条
Development of a Universal Influenza Vaccine Against Influenza A and B Viruses
-
批准号:10053298
-
项目类别:
-
资助金额:$68.9万
-
财政年份:2018
-
负责人:Harvinder Singh Gill
-
依托单位:
Microneedles for treatment of peanut allergy
-
批准号:9662551
-
项目类别:
-
资助金额:$71.85万
-
财政年份:2018
-
负责人:Harvinder Singh Gill
-
依托单位:
Development of a Universal Influenza Vaccine Against Influenza A and B Viruses
-
批准号:10291415
-
项目类别:
-
资助金额:$68.74万
-
财政年份:2018
-
负责人:Harvinder Singh Gill
-
依托单位:
Microneedles for treatment of peanut allergy
-
批准号:10219057
-
项目类别:
-
资助金额:$64.98万
-
财政年份:2018
-
负责人:Harvinder Singh Gill
-
依托单位:
Development of a Universal Influenza Vaccine Against Influenza A and B Viruses
-
批准号:10519103
-
项目类别:
-
资助金额:$66.8万
-
财政年份:2018
-
负责人:Harvinder Singh Gill
-
依托单位:
Microneedles for treatment of peanut allergy
-
批准号:10471226
-
项目类别:
-
资助金额:$63.27万
-
财政年份:2018
-
负责人:Harvinder Singh Gill
-
依托单位:
Engineering an intranasal universal influenza vaccine
-
批准号:9526306
-
项目类别:
-
资助金额:$58.43万
-
财政年份:2017
-
负责人:Harvinder Singh Gill
-
依托单位:
Nanoengineered virus-mimics as templates for design of a universal influenza A va
-
批准号:8499243
-
项目类别:
-
资助金额:$13.26万
-
财政年份:2012
-
负责人:Harvinder Singh Gill
-
依托单位:
Nanoengineered virus-mimics as templates for design of a universal influenza A va
-
批准号:8285558
-
项目类别:
-
资助金额:$21.51万
-
财政年份:2012
-
负责人:Harvinder Singh Gill
-
依托单位:
Targeting the oral cavity epithelium for inducing mucosal immunity against HIV
-
批准号:8249376
-
项目类别:
-
资助金额:$10.61万
-
财政年份:2011
-
负责人:Harvinder Singh Gill
-
依托单位:
Targeting the oral cavity epithelium for inducing mucosal immunity against HIV
-
批准号:8141631
-
项目类别:
-
资助金额:$10.59万
-
财政年份:2011
-
负责人:Harvinder Singh Gill
-
依托单位:
海外基金